Vancomycin Resistant Enterococci (VRE) are a growing public health threat and pose a risk to patient safety in healthcare facilities1
In healthcare settings, colonized patients and environmental contamination contribute to VRE spread1
High-risk patients colonized with VRE have 24 times increased infection risk2
Infections caused by VRE are associated with high mortality3
VRE has an impact on patient length-of-stay, and in turn, hospitalization costs3
1 Levitus M, et al. Vancomycin-Resistant Enterococci. StatPearls July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK513233/?report=reader#_NBK513233_pubdet. Accessed December 11, 2023
2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016 Dec;4(1):ofw246.
3 Eichel V,M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. Journal of Hospital Infection 141 (2023) 119e128
The Solution
The Xpert vanA test is a rapid and accurate method for detection of VRE colonization among high-risk admissions and for screening during outbreaks of VRE
Fast, active screening of high-risk patients to prevent the spread of VRE and better manage colonized and infected patients4
4 Babady N,E, et al. Performance Characteristics of the Cepheid Xpert vanA Assay for Rapid Identification of Patients at High Risk for Carriage of Vancomycin-Resistant Enterococci. Journal of Clinical Microbiology, November 2012 Volume 50 Number 11 p. 3659–3663
The Impact
Rapid PCR results facilitate more efficient infection control surveillance programs5
– 93% reduction of turnaround time from 70.5h with chromogenic agar culture to 4.6h– High negative predictive value allows for better management of non-colonized patients– Decreased the number of contact patients thereby preventing VRE transmission– 94% reduction in overall cost ($15,645 with culture vs $952*)
ompared to culture, faster time to result may support more effective patient management: more isolation and transmission isk days saved6:
– 141 saved isolation days and 292 saved transmission risk days
5 Birgand G, et al. Lucet JC. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrobial Resistant and Infection Control. 2013 Nov ; 2:30.
6 Holzknecht BJ, Hansen DS, Nielsen L, Kailow A, Jarløv JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59
* 1€=1.09$, conversion rate December 15th 2023Test
Related Products
Xpert MRSA NxG
Active MRSA surveillance testing in about an hour
Learn more
Xpert FII & FV
30-Minute Test for Genetic Risk of Thrombosis
Learn more
Xpert SA Nasal Complete
Pre-surgical S. aureus and MRSA in about an hour
Learn more
Xpert Xpress CoV-2/Flu/RSV plus
Actionable rapid respiratory results to meet the challenges of co-circulating respiratory viruses
Learn more
Xpert Norovirus
Fast and accurate identification of Norovirus GI & GII in as little as one hour* *With early assay termination for positive results. Reporting negative results in 90 minutes.
Learn more
Xpert MTB/RIF
Accurate Detection of MTB and Rifampin Resistance Mutations
Learn more
Xpert C. difficile/Epi
45-minute detection of toxigenic Clostridioides difficile and presumptive identification of 027/NAP1/BI strains
Learn more
Xpert C. difficile
Detection of toxigenic Clostridioides difficile in 43 minutes
Learn more
Xpert MRSA/SA Blood Culture
Accurate detection of MRSA and SA in positive blood culture specimens in about an hour
Learn more
Xpert Carba-R
Detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48 in 48 minutes
Learn more
Xpert MRSA/SA SSTI
Detect MRSA & SA Skin and Soft Tissue Infections In About One Hour